AbbVie stock: RBC keeps Buy rating for AbbVie stock at USD 280.00

Published on 10/21/2026 at 17:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 16.99 billion, up 10.20 percent. AbbVie stock costs EUR 253.55 on October 21, 2026, down 1.34 percent versus Xetra close.

Analyst target and reporting date

RBC Capital Markets kept a Buy rating and a USD 280.00 target on October 13, 2026.
AbbVie reported USD 16.99 billion in second-quarter 2026 revenue, up 10.20 percent year over year.
AbbVie stock costs EUR 253.55 at Lang & Schwarz on October 21, 2026 at 5:11 p.m. CEST, 1.34 percent below the Xetra close of October 20, 2026 at EUR 257.00.
AbbVie will announce third-quarter 2026 results on October 30, 2026.

Flatlay-Produktfoto mit generischen Blisterpackungen, Ampullen, Pipette und abstraktem Wertpapierschein — AbbVie Inc. US00287Y1091 Flatlay generische Blisterpackungen Ampullen Pipette Aktien Zertifikat und ISIN Karte, Illustration mit AI erstellt.

AbbVie Inc. (US00287Y1091) retained a Buy rating from RBC Capital Markets on October 13, 2026, with a USD 280.00 price target, unchanged from USD 260.00, according to Zacks. The target is 1.56 percent below the USD 284.45 primary-exchange price, while AbbVie was trading at EUR 253.55 at Lang & Schwarz on October 21, 2026 at 5:11 p.m. CEST, down 1.34 percent versus the Xetra close of October 20, 2026 at EUR 257.00.

Second-quarter growth remains central

AbbVie reported USD 16.99 billion in total revenue for the second quarter of 2026, an increase of 10.20 percent from the same quarter a year earlier. Adjusted earnings per share reached USD 3.65, USD 0.06 above the company guidance midpoint, while adjusted operating margin was 48.30 percent, according to the Yahoo Finance transcript dated July 31, 2026.

The mix matters for the coming report. Skyrizi sales rose 24.00 percent operationally to USD 5.50 billion, while Rinvoq sales increased 23.70 percent to more than USD 2.50 billion. Humira revenue fell 36.10 percent operationally to USD 756.00 million in the same quarter, keeping replacement growth at the center of the earnings debate.

Stock sits below its yearly high

At USD 284.45 on the NYSE at 11:20 a.m. ET on October 21, 2026, AbbVie stood 2.39 percent below its 52-week high of USD 291.40 and 49.20 percent above its 52-week low of USD 190.75. Trading volume was 943,805 shares at that timestamp. The market capitalization was USD 502.7 billion.

When does AbbVie report?

AbbVie will announce its third-quarter 2026 results before the US market opens on October 30, 2026, according to the company release dated October 1, 2026, published by AbbVie. Management previously guided to third-quarter adjusted earnings per share of USD 3.84 to USD 3.88 and full-year adjusted earnings per share of USD 13.87 to USD 14.07.

AbbVie's valuation remains higher than several large pharmaceutical peers, with a price-to-earnings ratio of 80.11 and a dividend yield of 2.00 percent as of October 21, 2026. The next earnings release will test whether Skyrizi and Rinvoq can continue to offset pressure on Humira and oncology sales.

Euro quote after the Xetra close

AbbVie was trading at EUR 253.55 at Lang & Schwarz on October 21, 2026 at 5:11 p.m. CEST, 1.34 percent below the Xetra close of October 20, 2026 at EUR 257.00. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.